Ventana Medical Systems has entered into master collaboration agreement with Astellas Pharma to develop novel automated tissue diagnostics in support of therapeutic compounds in development.
Initial projects related to this agreement will support early-stage clinical trials for the Astellas therapeutic compound ASP5878, a novel small-molecule fibroblast growth factor receptor (FGFR) inhibitor which has been shown to block the kinase activities of FGFR1, FGFR2, FGFR3 and FGFR4.
|Searching for more deal information? Current Partnering offers the following options:
Ventana will develop, in parallel, an immunohistochemistry (IHC) test identifying FGF19 in certain solid tumors.
Financial terms of this agreement were not disclosed.
For further deal information visit Current Agreements (subscription required)
Scorecard: Top partnering deals by value in 2015
View: Top biotech companies